Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 324

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 324
---
 collect from their health insurers. |

After this offering, DiamiR
plans to expand its team with reimbursement and regulatory experts, and DiamiR will work diligently towards securing reimbursement based
on current regulations. DiamiR plans on creating a clinical dossier compromised of peer-review publications on the following 4 key areas:

| 1. | Analytical Validation — The assay correctly          
 and reproducibly tests for specific analytes/targets |

| 2. | Clinical Validation — The assay’s target 
 analytes rule-in or rule-out a disease   |

| 3. | Clinical utility — The test results in changes 
 with physician behavior or patient treatment   |

| 4. | Cost-effectiveness and economic health benefits — The                                                                   
 test saves the healthcare system money, either by reducing unnecessary treatment, improving outcomes or other measures. |

A robust clinical dossier is
a critical tool for successful reimbursement discussions with payors. DiamiR’s management team has experience with, and understands
the process, and will focus its efforts to gain insurance coverage in a timely manner.

Accurate early diagnostics
of AD will improve effectiveness of future cost of care for AD. The current cost of care for AD and AD related issues is estimated
to be around $345B annually and is expected to reach $1Trillion by 2050.

| * | https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf |

<div align='center'>187</div>

Strategies and products designed
for early identification of AD are key to reducing the financial burden of AD to payors, caregivers, and families of those impacted by
this disease. Thus, the use of CogniMIR and DiamiR’s other future tests align with payors’ goals to improve
the affordability and efficacy of diagnosis and treatment for AD.

Other supportive publications
on cost effectiveness of early intervention include:

“Evaluation of the Cost-effectiveness
of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.” Ito et. al. JAMA Netw
Open. 2021 Oct; 4(10): e2129392. Published online 2021 Oct.22. doi: 10.1001/jamanetworkopen.2021.29392PMCID: PMC8536950. PMID: 34677596

“Assessing the Cost-effectiveness
of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Sym